1 and seven transplant recipients with chronic
hepatitis E.
2 or the development of new strategies against
hepatitis E.
3 injury in an era of increasing awareness of
hepatitis E.
4 en made in the prevention of hepatitis A and
hepatitis E.
5 Moldova, a country without reported cases of
hepatitis E.
6 eveloped that offer the potential to prevent
hepatitis E.
7 I interferon in preventing symptomatic acute
hepatitis E.
8 ome organization and pathogenesis in chronic
hepatitis E.
9 oping effective therapeutics against chronic
hepatitis E.
10 rovide a basis for developing treatments for
hepatitis E.
11 decompensated graft cirrhosis due to chronic
hepatitis E.
12 id monotherapy for acute liver injury due to
hepatitis E.
13 ed cases of possible transfusion-transmitted
hepatitis E.
14 tion: (1) 24 patients with symptomatic acute
hepatitis E; (
2) 12 patients with HEV-associated Parsona
15 itis E virus (HEV) is the causative agent of
hepatitis E,
a major form of viral hepatitis in developi
16 nce entropy and genetic distances during the
hepatitis E acute phase were higher in patients whose in
17 endemic, with frequent seasonal epidemics of
hepatitis E and continuous sporadic cases.
18 yphoid and parathyroid, leishmaniasis, acute
hepatitis E,
and HIV/AIDS), we used natural history mode
19 ra obtained 2 months to 13 years after acute
hepatitis E,
and postinoculation chimpanzee sera), known
20 BcAg]) and the secreted nonparticulate form (
hepatitis e antigen [HBeAg]).
21 esponses are absent in patients with chronic
hepatitis E but become detectable after viral clearance;
22 In total, 2713 acute
hepatitis E cases were diagnosed, of which 1376 were ind
23 Epidemic forms of
hepatitis E cause high mortality among pregnant people,
24 wide range of pathogenic viruses, including
hepatitis E,
Chikungunya, Rift Valley Fever virus and SA
25 How frequently does chronic
hepatitis E develop among human immunodeficiency virus-i
26 In a setting without endemic
hepatitis E disease, there was no evidence that anti-HEV
27 vaccine and its effectiveness in preventing
hepatitis E during pregnancy.
28 Hepatitis E has a worldwide distribution and causes subs
29 Hepatitis E has been considered to be a travel-associate
30 Autochthonous
hepatitis E has been observed with growing incidence in
31 Sporadic autochthonous cases of
hepatitis E have been reported recently in the United St
32 The dynamics of
hepatitis E have changed recently with an increase in th
33 An increasing incidence of endemic
hepatitis E (
HE) has been reported in developed countrie
34 High
hepatitis E (
HEV) seroprevalence has been reported in th
35 HEV-239 elicited a robust
hepatitis E IgG response that peaked 1 month following t
36 A case of acute
hepatitis E in a researcher following a scalpel injury w
37 pregnant participants were confirmed to have
hepatitis E in either treatment group.
38 , it can have a role in curbing outbreaks of
hepatitis E in humanitarian crises.
39 itis E virus (HEV) is the causative agent of
hepatitis E in humans and is the leading cause of enteri
40 itis E virus (HEV) is the causative agent of
hepatitis E in humans and the leading cause for acute vi
41 py to ribavirin for the treatment of chronic
hepatitis E in immunocompromised patients.
42 aimed to assess whether vaccination against
hepatitis E in pregnancy increases the risk of fetal los
43 To investigate the time trends of
hepatitis E in southeastern Germany, we performed anti-H
44 The primary endpoint was
hepatitis E in the pregnant, per-protocol population (th
45 ed for new treatment options to cure chronic
hepatitis E in the setting of organ transplantation.
46 ly recovered from two patients with clinical
hepatitis E in the United States shared >/=97% amino aci
47 e and liver transplantation in patients with
hepatitis E-
induced acute liver injury and high-grade in
48 ere evaluated for evidence of hepatitis C or
hepatitis E infection and for evidence of severe or prol
49 loping world, viral causes predominate, with
hepatitis E infection recognised as a common cause in ma
50 d treatment, acute liver injury improved and
hepatitis E infection resolved.
51 Increasing evidence indicates that
hepatitis E is a zoonotic disease.
52 We conclude that chronic
hepatitis E is associated with impaired HEV-specific T-c
53 s trapped in Nepal's Kathmandu Valley, where
hepatitis E is hyperendemic, for HEV infection.
54 thermore, a differential diagnosis including
hepatitis E is mandatory in all alloHSCT patients with s
55 Clinically,
hepatitis E is not easily distinguished from other types
56 is genetically closely related to human HEV,
hepatitis E is now considered a zoonotic disease.
57 HEV is common in the US population, although
hepatitis E is rarely reported.
58 Hepatitis E is recognized as a zoonosis, and swine are k
59 The topic of
hepatitis E is therefore re-emerging and has raised the
60 IMPORTANCE
Hepatitis E is usually a self-resolving acute disease; h
61 atitis E virus (HEV), the causative agent of
hepatitis E,
is an important public health concern in ma
62 The disease caused by HEV,
hepatitis E,
is an important public health problem in de
63 dan virus, hantaviruses [Hantaan and Seoul],
hepatitis E,
Marburg, Nipah virus, o'nyong-nyong virus,
64 ion, unrecognized hepatitis D infection, and
hepatitis E may all represent emergent areas of concern.
65 However, in individual cases,
hepatitis E may lead to life-threatening acute liver fai
66 identified in industrialized countries, but
Hepatitis E now is reported increasingly throughout West
67 atitis E virus (HEV), the causative agent of
hepatitis E,
on IFN signaling have not been investigated
68 assembled from blood donors (n = 372), acute
hepatitis E patients (n = 94), five laboratory animals (
69 tic increases in transaminases (n=2; one was
hepatitis E positive).
70 Hepatitis E represents an alternative diagnosis to some
71 Chronic
hepatitis E represents an emerging challenge in organ tr
72 Chronic
hepatitis E should be regarded as another opportunistic
73 Several cases of acute
hepatitis E showed portal and periportal hepatitis, with
74 cute liver injury caused by an autochthonous
hepatitis E that resolved under steroid treatment.
75 used to determine the cost-effectiveness of
hepatitis E vaccination and other interventions.
76 A
hepatitis E vaccine could become a powerful new tool in
77 A novel recombinant
hepatitis E vaccine was shown to be safe and effective i
78 Hepatitis E viral (HEV) infection imposes a heavy health
79 Most cases of
hepatitis E viral (HEV) infection in developed countries
80 Acute viral hepatitis resulting due to
hepatitis E viral infection (AVH-E) is often serious in
81 with in vitro transcribed viral genomes, and
hepatitis E virions were released into the culture mediu
82 ted in 75 of 108 (69%) patients, antibody to
hepatitis E virus (anti-HEV) in three patients (3%), and
83 To evaluate antibody to
hepatitis E virus (anti-HEV) seroreactivity, 5000 US blo
84 Baseline prevalence of antibody to
hepatitis E virus (anti-HEV) was 22.5%.
85 tibodies to hepatitis A virus (anti-HAV) and
hepatitis E virus (anti-HEV) was 65.2% (95% CI, 64.2%-66
86 mance of existing assays for antibody to the
hepatitis E virus (anti-HEV).
87 haracterized a novel virus, designated avian
hepatitis E virus (avian HEV), from chickens with hepati
88 association between serum antibodies against
hepatitis E virus (HEV) and central nervous system (CNS)
89 odies against the emerging zoonotic pathogen
hepatitis E virus (HEV) and enteropathogenic Yersinia sp
90 The thermal stability of virulent
hepatitis E virus (HEV) and hepatitis A virus (HAV) was
91 he host responses to two dissimilar viruses,
hepatitis E virus (HEV) and hepatitis C virus (HCV), wer
92 s have shown a relatively high prevalence of
hepatitis E virus (HEV) antibody.
93 Hepatitis E virus (HEV) can chronically infect immunocom
94 -strands similar to what was observed in the
hepatitis E virus (HEV) capsid structure.
95 Hepatitis E virus (HEV) causes both endemic and epidemic
96 Hepatitis E virus (HEV) causes outbreaks of jaundice ass
97 Hepatitis E virus (HEV) causes roughly 20 million yearly
98 Hepatitis E virus (HEV) constitutes a substantial public
99 The RNA genome of the
hepatitis E virus (HEV) contains a hypervariable region
100 ntigen derived from the Meng strain of swine
hepatitis E virus (HEV) differs from that of the Sar-55
101 All patients cleared the
hepatitis E virus (HEV) except for 2 (nonresponders); 1
102 tment options for patients who fail to clear
hepatitis E virus (HEV) following reduction of immunosup
103 Hepatitis E Virus (HEV) genome encodes three proteins in
104 L) structure in the intergenic region of the
hepatitis E virus (HEV) genome in virus replication were
105 Hepatitis E virus (HEV) genotype 1 (HEV-1) infection in
106 Hepatitis E virus (HEV) genotype 3 infections are freque
107 The prevalence of
hepatitis E virus (HEV) genotype 3 infections in the Eng
108 ports of food-borne zoonotic transmission of
hepatitis E virus (HEV) genotype 3, which causes chronic
109 We estimated the global burden of
hepatitis E virus (HEV) genotypes 1 and 2 in 2005.
110 Hepatitis E virus (HEV) has been recognized as a threat
111 Hepatitis E virus (HEV) has emerged as a cause of chroni
112 Hepatitis E virus (HEV) has recently been cloned and seq
113 Moreover, a high prevalence (17%) of
hepatitis E virus (HEV) immunoglobulin G antibodies (ant
114 eriod, 38 of 48 persons testing positive for
hepatitis E virus (HEV) immunoglobulin M in Los Angeles
115 sceptible humans may serve as a reservoir of
hepatitis E virus (HEV) in areas in which HEV is endemic
116 ce and molecular characterisation studies of
hepatitis E virus (HEV) in England and Wales have been u
117 The recent identification of antibody to
hepatitis E virus (HEV) in pigs, sheep, and cattle and c
118 amination and evaluate the dispersion of the
hepatitis E virus (HEV) in the environment.
119 The awareness of
hepatitis E virus (HEV) increased significantly in the l
120 Hepatitis E virus (HEV) induces acute hepatitis in human
121 Transplant recipients are at risk of
hepatitis E virus (HEV) infection and could be vulnerabl
122 rin is highly efficient for treating chronic
hepatitis E virus (HEV) infection and shows that HEV RNA
123 However,
hepatitis E virus (HEV) infection can also be acquired i
124 Hepatitis E virus (HEV) infection causes major epidemics
125 ntiviral immunity and immunopathology during
hepatitis E virus (HEV) infection determines important c
126 Hepatitis E virus (HEV) infection has been proposed as a
127 ical and laboratory features, and outcome of
hepatitis E virus (HEV) infection in children.
128 Hepatitis E virus (HEV) infection in pregnant women has
129 nd a relatively high seroprevalence (21%) of
hepatitis E virus (HEV) infection in the U.S. general po
130 Acute
hepatitis E virus (HEV) infection is a leading cause of
131 BACKGROUND & AIMS:
Hepatitis E virus (HEV) infection is a major cause of ac
132 Chronic
hepatitis E virus (HEV) infection is a significant clini
133 Hepatitis E virus (HEV) infection is an emerging disease
134 Persistent
hepatitis E virus (HEV) infection is described in a numb
135 Hepatitis E virus (HEV) infection is increasingly being
136 Hepatitis E virus (HEV) infection is the leading cause o
137 Hepatitis E virus (HEV) infection is usually self-limite
138 Secondary spread of
hepatitis E virus (HEV) infection occurs often in endemi
139 nsitivity to exogenous type I IFN.IMPORTANCE
Hepatitis E virus (HEV) infection typically causes self-
140 Hepatitis E virus (HEV) infection usually results in a s
141 protective efficacy of a DNA vaccine against
hepatitis E virus (HEV) infection was tested in cynomolg
142 Prevalence of antibody and risk factors to
hepatitis E virus (HEV) infection were determined in a c
143 s currently recommended for treating chronic
hepatitis E virus (HEV) infection.
144 There is no established therapy for
hepatitis E virus (HEV) infection.
145 Hepatitis E virus (HEV) infections are a major cause of
146 Antiviral treatment options for chronic
Hepatitis E Virus (HEV) infections are limited and immun
147 Hepatitis E virus (HEV) infections are one of the most c
148 Among
hepatitis E virus (HEV) infections diagnosed in 2011 by
149 Transfusion-transmitted
hepatitis E virus (HEV) infections have raised many conc
150 lid-organ-transplant recipients with chronic
hepatitis E virus (HEV) infections were given ribavirin
151 There is little knowledge about how
hepatitis E virus (HEV) inhibits induction of host IFNs,
152 Hepatitis E virus (HEV) is a 7.2-kb positive-sense, sing
153 Hepatitis E virus (HEV) is a causative agent of acute he
154 Hepatitis E virus (HEV) is a human pathogen that causes
155 Hepatitis E virus (HEV) is a long-neglected RNA virus an
156 Hepatitis E virus (HEV) is a major cause of acute hepati
157 Hepatitis E virus (HEV) is a major cause of acute hepati
158 Hepatitis E virus (HEV) is a major cause of acute viral
159 Hepatitis E virus (HEV) is a major public health concern
160 The ORF3 protein of
hepatitis E virus (HEV) is a multifunctional protein imp
161 Hepatitis E virus (HEV) is a new causative agent of chro
162 Hepatitis E virus (HEV) is a single-strand positive-sens
163 Hepatitis E virus (HEV) is a worldwide zoonotic and publ
164 The
hepatitis E virus (HEV) is an emergent zoonotic virus ca
165 Hepatitis E virus (HEV) is an emerging virus causing epi
166 complex mechanisms of HEV biology.IMPORTANCE
Hepatitis E virus (HEV) is an emerging virus found predo
167 Hepatitis E virus (HEV) is an important but extremely un
168 Hepatitis E virus (HEV) is an important but extremely un
169 Hepatitis E virus (HEV) is an important but understudied
170 Hepatitis E virus (HEV) is an important cause of enteric
171 Hepatitis E virus (HEV) is an important human pathogen,
172 Hepatitis E virus (HEV) is an important human pathogen.
173 Hepatitis E virus (HEV) is an important public health co
174 Hepatitis E virus (HEV) is an RNA virus responsible for
175 Hepatitis E virus (HEV) is an unclassified virus with a
176 Hepatitis E virus (HEV) is believed to be transmitted by
177 Exposure to
hepatitis E virus (HEV) is common in the United States,
178 Hepatitis E virus (HEV) is considered a zoonotic infecti
179 Hepatitis E virus (HEV) is endemic in many developing an
180 Hepatitis E virus (HEV) is endemic in many resource-poor
181 Hepatitis E virus (HEV) is increasingly acknowledged as
182 ferent hosts in genotypes 3 and 4.IMPORTANCE
Hepatitis E virus (HEV) is increasingly recognized as a
183 Hepatitis E virus (HEV) is one of the most common causes
184 Hepatitis E virus (HEV) is prevalent and causes disease
185 Although
hepatitis E virus (HEV) is regarded as a self-limiting i
186 Hepatitis E virus (HEV) is the causative agent of hepati
187 Hepatitis E virus (HEV) is the causative agent of hepati
188 Hepatitis E virus (HEV) is the causative agent of hepati
189 Hepatitis E virus (HEV) is the leading cause of enterica
190 Avian
hepatitis E virus (HEV) is the main causative agent of b
191 Hepatitis E virus (HEV) is the major cause of entericall
192 Hepatitis E virus (HEV) is the most common cause of acut
193 Hepatitis E virus (HEV) is the most common cause of acut
194 Hepatitis E virus (HEV) is the most common cause of acut
195 The RNA virus,
hepatitis E virus (HEV) is the most or second-most impor
196 Hepatitis E virus (HEV) is yearly responsible for approx
197 Hepatitis E virus (HEV) lacks approved virus-specific an
198 Hepatitis E virus (HEV) leads to high mortality in pregn
199 To determine the initiation strategy of the
hepatitis E virus (HEV) open reading frame 3 (ORF3), we
200 The
hepatitis E virus (HEV) polyproline region (PPR) is an i
201 As a positive-strand RNA virus,
hepatitis E virus (HEV) produces an intermediate negativ
202 urther, we show that enterically transmitted
hepatitis E virus (HEV) progeny particles are secreted b
203 The antigenic composition of the
hepatitis E virus (HEV) protein encoded by open reading
204 Hepatitis E virus (HEV) recently has been shown to be an
205 Hepatitis E virus (HEV) replication is not well understo
206 The mechanism of
hepatitis E virus (HEV) replication remains largely unkn
207 The
hepatitis E virus (HEV) RNA concentrations were determin
208 Hepatitis E virus (HEV) RNA replication occurred in seve
209 Hepatitis E virus (HEV) seroprevalences of 0.3%-53% were
210 Here, we report that the macro domain from
hepatitis E virus (HEV) serves as an ADP-ribose-protein
211 The
hepatitis E virus (HEV) sheds into feces as nonenveloped
212 The classification of
hepatitis E virus (HEV) variants is currently in transit
213 with HUE (58.3%) and the pooled library, and
hepatitis E virus (HEV) was detected in 2 individuals wi
214 nst the ORF2 protein of the SAR-55 strain of
hepatitis E virus (HEV) were isolated by phage display f
215 onstitutes an attractive control measure for
hepatitis E virus (HEV), a major cause of maternal and p
216 Avian
hepatitis E virus (HEV), a novel virus identified from c
217 Hepatitis E virus (HEV), a single-stranded positive-sens
218 Hepatitis E virus (HEV), a small, non-enveloped RNA viru
219 Hepatitis E virus (HEV), an emerging zoonotic pathogen a
220 Hepatitis E virus (HEV), an enterically transmitted RNA
221 ut how broadly enzootic its causative agent,
hepatitis E virus (HEV), is remains controversial.
222 Hepatitis E virus (HEV), rotavirus (RV), and astrovirus
223 The effects of
hepatitis E virus (HEV), the causative agent of hepatiti
224 Hepatitis E virus (HEV), the causative agent of hepatiti
225 immunocompromised individuals infected with
hepatitis E virus (HEV)-g3.
226 s a striking resemblance to the structure of
hepatitis E virus (HEV)-like particles, as previously pr
227 tudy of Hecolin(R), the licensed vaccine for
hepatitis E virus (HEV).
228 Hepatitis E virus (HEV; family Hepeviridae) infections c
229 Prior to the recent discovery of the swine
hepatitis E virus (swine HEV) in pigs from the midwester
230 Swine
hepatitis E virus (swine HEV), the first animal strain o
231 A novel virus, designated swine
hepatitis E virus (swine HEV), was identified in pigs.
232 gical and molecular techniques (detection of
hepatitis E virus [HEV] RNA from stool and serum samples
233 ectious cDNA clone of a genotype 3 strain of
hepatitis E virus adapted to growth in HepG2/C3A human h
234 We test the infections of two RNA viruses,
hepatitis E virus and SARS-CoV-2, and one DNA virus, mon
235 elm mottle virus, in animal viruses like the
hepatitis E virus and the caprine encephalitis virus, an
236 If the occurrence of
hepatitis E virus antibody (anti-HEV) in regions where t
237 Based on a
hepatitis E virus capsid model, we performed homology mo
238 a-barrel structure that is also found in the
hepatitis E virus capsid protrusions, suggesting a close
239 owever, recent work on hepatitis A virus and
hepatitis E virus challenges this long-held tenet.
240 , the ICTV approved a proposal to remove the
hepatitis E virus from the Caliciviridae into an "unassi
241 Hepatitis E virus genotype 1 strain Sar55 replicated in
242 Indigenous, foodborne transmission of
hepatitis E virus genotype 3 (HEV G3) has become recogni
243 that sofosbuvir inhibits the replication of
hepatitis E virus genotype 3 both in subgenomic replicon
244 Infection with
hepatitis E virus genotype 3 may result in chronic hepat
245 Hepatitis E virus has been reported to result in chronic
246 Hepatitis E virus IgM and IgG reactivity was determined.
247 Hepatitis E virus IgM and IgG reactivity.
248 The seroprevalence of antibody to
hepatitis E virus in this population was 13.6%; to Barto
249 ral blood and liver tissue revealed an acute
hepatitis E virus infection (genotype 3).
250 Hepatitis E virus infection (HEV) is an emerging problem
251 Hepatitis E virus infection causes an acute hepatitis wi
252 Ribavirin is efficient at treating chronic
hepatitis E virus infection in solid-organ transplant pa
253 ts with a solid-organ transplant and chronic
hepatitis E virus infection were given ribavirin for 3 m
254 ures of inflammatory cell death triggered by
hepatitis E virus infection when integrated with pro-inf
255 Chronic
hepatitis E virus infection with rapid progression to ci
256 Hepatitis E virus is a nonenveloped RNA virus.
257 Hepatitis E virus recombinant genomes transcribed in vit
258 ct the multifunctional role of human bile on
hepatitis E virus replication and the inflammatory respo
259 Hepatitis E virus replicons containing the neomycin resi
260 Hepatitis E virus RNA levels also remained detectable in
261 ul new tool in the prevention and control of
hepatitis E virus transmission and disease.
262 ablishing the safety and immunogenicity of a
hepatitis E virus vaccine in multiple populations could
263 ly efficiently transfected and infected with
hepatitis E virus was identified.
264 An infectious cDNA clone of
hepatitis E virus was mutated in order to prevent synthe
265 rpes simplex virus-1/2, human herpesvirus 8,
hepatitis E virus, parvovirus B19).
266 related to the P1 domain in calicivirus and
hepatitis E virus, suggesting a possible evolutionary re
267 In the case of
hepatitis E virus, the adjacent viral helicase domain dr
268 Hepatitis E Virus-like particles self-assemble in to non
269 We also recruited non-
hepatitis E virus-related pregnant (P), ALF-NE (n = 5) a
270 ulation: human T-cell leukemia virus type 1;
hepatitis E virus; bocavirus; KI and WU polyomaviruses;
271 itis-B virus (HBV), hepatitis-C virus (HCV),
hepatitis-E virus (HEV), dengue virus (DENV), and West N
272 en-free pigs were inoculated with one of two
hepatitis E viruses (HEV) (one recovered from a pig and
273 Genotype 1
hepatitis E viruses (HEVs) are restricted to primate hos
274 t mass reactive vaccination campaign against
hepatitis E was conducted in South Sudan with the HEV239
275 ast decade, an increasing frequency of acute
hepatitis E was noted in Germany and other European coun
276 Until recently,
hepatitis E was rarely identified in industrialized coun
277 ients with anti-HEV IgM indicated that acute
hepatitis E was the most likely diagnosis for 7 and migh
278 On 11 December 2013, 3 clustered cases of
hepatitis E were reported on a French coastal island.
279 erived food products to post-transplantation
hepatitis E,
which, if detected at early stages, can be
280 ples collected from 15 patients with chronic
hepatitis E who were recipients of solid-organ transplan